WO2021234055A1 - Compositions et méthodes pour fournir des bénéfices pour le soin de la peau - Google Patents

Compositions et méthodes pour fournir des bénéfices pour le soin de la peau Download PDF

Info

Publication number
WO2021234055A1
WO2021234055A1 PCT/EP2021/063387 EP2021063387W WO2021234055A1 WO 2021234055 A1 WO2021234055 A1 WO 2021234055A1 EP 2021063387 W EP2021063387 W EP 2021063387W WO 2021234055 A1 WO2021234055 A1 WO 2021234055A1
Authority
WO
WIPO (PCT)
Prior art keywords
biotin
growth
skin
anhydride
composition
Prior art date
Application number
PCT/EP2021/063387
Other languages
English (en)
Inventor
Pamela GAMBA
Joanne Elizabeth HUNT
Alexander Gordon James
Barry Murphy
Emily Grace SMITH
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Priority to EP21726914.1A priority Critical patent/EP4153124A1/fr
Publication of WO2021234055A1 publication Critical patent/WO2021234055A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to compositions and methods for providing skin care benefits by selectively supporting the growth of beneficial commensal microbial strains in the human cutaneous microbiome.
  • Human skin harbours many diverse microorganisms, which colonize the stratum comeum of the epidermis and skin appendages such as sweat glands and hair follicles.
  • the total of microorganisms in and on our skin is termed the cutaneous microbiota, and the skin microbiome is their collective genome.
  • Microbial colonization is differentially shaped by the physiological and topological variation of the skin, and varies systematically among different skin habitats, such as between dry, moist, and sebaceous skin.
  • the human axillae (underarms) are covered by squames, hair shafts and follicles, eccrine, apocrine and sebaceous glands.
  • the axillary area represents a distinct ecological niche characterized by warm, moist and nutritionally rich conditions. Salts, proteins, squalene, sterols, sterol esters, wax esters, a wide range of lipids and fatty acids are secreted, thus sustaining one of the highest densities of microorganisms on the body surface.
  • 3M3SH 3-methyl-3-sulfanylhexan-1-ol
  • S. epideimidis colonizes predominantly the axillae, head, and nares.
  • metabolic products of S. epidermidis including organic acids such as lactic acid, improve skin moisture retention, maintain a low acidic condition on the skin surface, and improve rough skin texture.
  • S. epidermidis is also considered to supplement the barrier function of the epidermis and inhibit the colonization of skin pathogens such as S. aureus through factors such as nutrient competition, production of antimicrobial peptides (AMPs), immunomodulatory properties (inhibition of inflammatory cytokine production) and enhanced expression of tight junction proteins.
  • AMPs antimicrobial peptides
  • C. aeries is another major skin commensal that prevents colonization and invasion of pathogens, via the hydrolysis of triglycerides in sebum and release of fatty acids that are antimicrobial and contribute to an acidic pH of the skin surface.
  • the main intervention strategy used for the treatment of armpit malodours is the topical application of deodorants and antiperspirants.
  • Deodorants reduce the bacterial counts in the axillae and add perfume to mask the malodour formation.
  • Antiperspirants additionally block the eccrine sweat glands to reduce the moisture production.
  • the present invention addresses this problem.
  • An objective of the present invention is to provide skin care benefits by selectively supporting the growth of beneficial commensal microbial strains in the human cutaneous microbiome.
  • the present invention provides a composition for providing skin care benefits by selectively supporting the growth of beneficial commensal microbial strains in the human cutaneous microbiome, the composition comprising at least one biotin binding compound and at least one precursor for biotin biosynthesis selected from pimelic acid, salts thereof or an anhydride thereof.
  • the invention also provides a method for providing skin care benefits by selectively supporting the growth of beneficial commensal microbial strains in the human cutaneous microbiome, the method comprising the simultaneous or sequential administration to the skin of at least one biotin binding compound and at least one precursor for biotin biosynthesis selected from pimelic acid, salts thereof or an anhydride thereof.
  • the invention also provides the use of pimelic acid, salts thereof or an anhydride thereof, optionally in combination with at least one biotin binding compound, for providing skin care benefits by selectively supporting the growth of beneficial commensal microbial strains in the human cutaneous microbiome.
  • skin is understood as the layers which comprise them, from the uppermost layer or stratum corneum to the lowermost layer or hypodermis, both inclusive. These layers are composed of different types of cells such as keratinocytes, fibroblasts, melanocytes, mastocytes, neurons and/or adipocytes, among others.
  • skin care means regulating and/or improving cosmetic qualities of the skin. These qualities are subject to regulation and/or improvement both in healthy subjects as well as those which present diseases or disorders of the skin (such as psoriasis, lichen planus, folliculitis or atopic dermatitis).
  • Examples of skin care benefits in the context of this invention include reducing and/or preventing cutaneous, especially axillary, malodour; providing a smoother, more even texture; improving the elasticity or resiliency of the skin; improving the firmness of the skin; reducing the oily, shiny, and/or dull appearance of skin; improving the hydration status or moisturization of the skin, improving the appearance of fine lines and/or wrinkles; improving skin exfoliation or desquamation; plumping the skin; improving skin barrier properties; improving skin tone; reducing the appearance of redness or skin blotches and improving the brightness, radiancy, or translucency of skin.
  • a preferred method according to this invention is a method for reducing and/or preventing axillary malodour by selectively supporting the growth of commensal S.epidermidis and/or C.acnes strains in the human axillary microbiome, the method comprising the simultaneous or sequential administration to axillary skin of at least one biotin binding compound and at least one precursor for biotin biosynthesis as described above.
  • compositions and methods of the invention are aimed at modulating natural interactions between beneficial commensal microbial strains in the human cutaneous microbiome (such as S. epidermidis and C. acnes) and other prominent members of the human cutaneous microbiome (such as S. hominis, S. haemolyticus and S. lugdunensis ).
  • beneficial commensal microbial strains in the human cutaneous microbiome such as S. epidermidis and C. acnes
  • other prominent members of the human cutaneous microbiome such as S. hominis, S. haemolyticus and S. lugdunensis .
  • composition of the invention comprises, inter alia, at least one biotin binding compound.
  • biotin binding compound denotes any compound which is capable of tightly but non-covalently binding to biotin (5-[(3aS,4S,6aR)-2-oxohexahydro-1 H-thieno[3,4-d]imidazol-4- yl]pentanoic acid).
  • biotin-binding compounds examples include biotin-binding proteins such as avidin-type molecules.
  • Avidin is a basic (pi c.10), homotetrameric glycoprotein (molecular weight 66-69 kDa) that contains terminal N-acetyl glucosamine and mannose residues. Each of the four subunits contains 128 amino acids and binds to biotin with high specificity and affinity (K d of about 10 15 M). Each subunit is composed of eight antiparallel b-strands that form a b-barrel, whose wide end binds to biotin. Avidin is originally derived from the eggs of birds, reptiles and amphibians.
  • avidin-type molecule encompasses native and recombinant forms of avidin as well as native and recombinant forms of avidin analogues such as streptavidin. Derived from Streptomyces avidinii, streptavidin is a c. 56 kDa non-glycosylated homotetrameric protein that binds to four biotins with a K d of about 10 15 M. Streptavidin has a tertiary/quatemary structure and amino acid arrangement similar to those of avidin and shows a moderate sequence homology level of c.30% sequence identity and 40% similarity with avidin.
  • Streptavidin is non-glycosylated and has a slightly acidic pi of about 5-6.
  • Neutravidin is another avidin analogue. It is the deglycosylated derivative of avidin and has a molecular weight of about 60 KDa. In the absence of the carbohydrate moieties, the pi of neutravidin is only slightly acidic (c.6.3).
  • Bradavidin II is an avidin analogue that may be isolated from Bradyrhizobium japonicum, a nitrogen-fixing bacterium found in the root nodules of the soybean plant. Bradavidin II shows a moderate amino acid similarity with avidin (38%) and streptavidin (32%) but exhibits the same biotin binding affinity as avidin.
  • Avidin analogues also include modified avidins prepared via covalent attachment to the available lysines of avidin.
  • modified avidins prepared via covalent attachment to the available lysines of avidin.
  • Examples include N-acyl avidins such as N-formyl, N-acetyl, N-phthalyl and N-succinyl avidin.
  • biotin-binding compounds for use in the invention are selected from native and recombinant forms of avidin.
  • composition of the invention comprises, inter alia, at least one precursor for biotin biosynthesis selected from pimelic acid, salts thereof or an anhydride thereof.
  • Pimelic acid is a straight-chained, 7-carbon saturated a, w-dicarboxylic acid (lUPAC name heptanedioic acid).
  • salts of pimelic acid include alkali metal salts (such as sodium, potassium and lithium salts); divalent metal salts (such as calcium, magnesium and zinc salts); ammonium salts; C1-C4 substituted ammonium salts (such as methyl-, dimethyl-, and trimethyl ammonium salts) and C1-C4 alkanolamine salts (such as ethanolamine, diethanolamine and triethanolamine salts).
  • alkali metal salts such as sodium, potassium and lithium salts
  • divalent metal salts such as calcium, magnesium and zinc salts
  • ammonium salts such as methyl-, dimethyl-, and trimethyl ammonium salts
  • C1-C4 alkanolamine salts such as ethanolamine, diethanolamine and triethanolamine salts
  • Preferred precursors for biotin biosynthesis for use in the invention are selected from pimelic acid, pimelic anhydride and mixtures thereof.
  • compositions for use in the invention can take a variety of forms suitable for topical application.
  • forms include a solid or liquid soap, a lotion, a spray, a cream, a gel, an emulsion, a cleansing liquid or cleansing milk, a deodorant, an antiperspirant, an ointment, a hair treatment or a shampoo.
  • References to a specific physical form of the composition denote the form of the composition at 25 °C and 1.0 bar, unless specified otherwise.
  • composition for use in the invention is a deodorant composition for reducing or preventing cutaneous, especially axillary, malodour.
  • compositions for use in the invention will generally contain from about 0.01% to about 10%, preferably from about 0.1 % to 1 % of the at least one biotin binding compound (by weight based on the total weight of the composition); and from about 0.01% to about 10%, preferably from about 0.1 % to 1 % of the at least one precursor for biotin biosynthesis selected from pimelic acid and/or salts thereof (by weight based on the total weight of the composition).
  • compositions for use in the invention will generally include a cosmetically acceptable vehicle.
  • Cosmetically acceptable means that the vehicle is suitable for topical application to the skin, has good aesthetic properties, is compatible with the at least one biotin binding compound and the at least one precursor for biotin biosynthesis selected from pimelic acid and/or salts thereof and any other ingredients, and will not cause any safety or toxicity concerns.
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase ora mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams and heavy creams.
  • Exemplary emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, polyol-in-silicone emulsions, silicone-in-polyol emulsions, polyol-in-oil emulsions, oil-in-polyol emulsions, wax-in-water emulsions and water-oil-water triple emulsions.
  • Preferred emulsions include oil-in-water emulsions and water-in-oil emulsions.
  • compositions in the form of an emulsion, and suitable for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
  • Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of polyols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl ole
  • compositions in the form of an emulsion, and suitable for use in the invention typically have an aqueous phase, which may also include one or more organic liquids that are miscible with water at room temperature (25°C).
  • exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C 2 -C 6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3-C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
  • compositions in the form of an emulsion, and suitable for use in the invention generally include surface active ingredients, such as emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
  • surface active ingredients such as emulsifiers and solubilizers
  • Emulsifiers that may be used to form O/Wor W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3-diisostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG- 30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, cetyl phosphate,
  • compositions for use in the invention may also be formulated in a single-phase carrier such as a hydrophobic or hydrophilic liquid.
  • Suitable hydrophobic liquid carriers include liquid polyorganosiloxanes, mineral oils, hydrogenated polyisobutene, polydecene, paraffins and isoparaffins of at least 10 carbon atoms, aliphatic or aromatic ester oils (such as isopropyl myristate, lauryl myristate, isopropyl palmitate, diisopropyl sebecate, diisopropyl adipate and Ci 2 to Ci 5 alkyl benzoates), polyglycol ethers (such as polyglycol butanol ethers) and mixtures thereof.
  • Suitable hydrophilic liquid carriers include water, monohydric or polyhydric aliphatic alcohols having 2 to 8, preferably 2 or 3 carbon atoms (such as ethanol and isopropanol, oligoglycol ethers having 2 to 5 repeat units (such as dipropylene glycol) and mixtures thereof.
  • Liquid form compositions for use in the invention may be thickened, for example using one or more water soluble or colloidally water soluble polymeric thickening agents.
  • Suitable water soluble or colloidally water soluble polymeric thickening agents include hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquatemium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, cross-linked polyacrylate polymers and polyacrylamide polymers.
  • Solid form compositions for use in the invention generally include one or more structurants, in an amount ranging from about 1 % to about 35% (by weight based on the total weight of the composition), depending upon the desired product consistency.
  • structurants include fatty acid gelling agents selected from saturated fatty acids or hydroxyacids containing from about 8 to 30 carbon atoms and their salts, esters or amides (such as sodium and potassium stearate, 12-hydroxystearic acid, esters of 12-hydroxystearic acid and amides of 12- hydroxystearic acid); saturated, unsubstituted monohydric fatty alcohols containing from about 8 to 30 carbon atoms (such as cetyl alcohol, myristyl alcohol and stearyl alcohol); acyl amino acid derivatives such as N-lauroyl-L-glutamic acid di-n-butylamide; amide derivatives of di ortribasic carboxylic acids such as alkyl N,N' dialkylsuccin
  • Compositions for use in the invention may include additional skin care actives for improving the physical and/or aesthetic characteristics of the skin.
  • additional skin care actives for improving the physical and/or aesthetic characteristics of the skin. Examples include vitamins, minerals and/or antioxidants, emollients, humectants, skin lightening agents, sunscreens, antiirritants, exfoliating agents, herbal extracts (such as pomegranate, white birch, green tea, chamomile and licorice extracts) and mixtures thereof.
  • compositions for use in the invention may include additional functional ingredients for improving the physical and/or aesthetic characteristics of the composition perse.
  • additional functional ingredients include inorganic pigments (such as titanium oxide, zirconium oxide, cerium oxide, zinc oxide, iron oxide, chromium oxide, manganese violet, ultramarine blue, chromium hydrate and ferric blue); organic pigments (such as carbon black and the organic lakes of barium, strontium, calcium or aluminium); pearlescent agents (such as mica coated with titanium oxide and/or iron oxide); dyes, preservatives (such as disodium EDTA, benzyl alcohol, methylparaben, phenoxyethanol, propylparaben, ethylparaben, butylparaben and isobutylparaben); pH adjusters and fragrances (such as essential oils, flower oils, natural extracts from resins, gums, balsams, beans, mosses and other plants, as well as synthetic aromatic materials).
  • inorganic pigments such as titanium oxide,
  • a composition for use in the invention may be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a liquid composition can be packaged in a bottle or a roll-ball applicator, or in a container fitted with a pump suitable for finger operation, or in a propellant-driven aerosol device.
  • Gel or cream compositions can be packaged in a non-deformable bottle or squeeze container, such as a tube or a lidded jar, or in an applicator having a dispensing head provided with at least one aperture through which the composition can be extruded under mild pressure.
  • Solid compositions may be shaped into a stick form which may be elevated out of a dispensing package and directly applied to the desired area of skin.
  • the composition is suitably applied to the skin, preferably facial or axillary skin, at the rate of one or two applications per day. Generally, an amount corresponding to about 1 to 2 ml of the composition per application is applied uniformly over the area of treatment twice daily for a period of at least 7 (seven) days, more preferably at least 30 (thirty) days.
  • biotin is an essential cofactor supporting growth of both bacteria.
  • both species grow to form visible single colonies.
  • biotin is not added to the medium no bacterial growth is observed after incubation of the plates at 37°C for 48 hours.
  • biotin binder avidin no bacterial growth is observed after incubation of the plates at 37°C for 48 hours.
  • pimelic acid is capable of replacing biotin as an essential cofactor supporting growth of S.epidermidis, but not in the case of S.hominis. Only S. epidermidis is able to grow in the presence of pimelic acid and absence of biotin. Similar results were obtained when pimelic anhydride was tested instead of pimelic acid.
  • pimelic acid (and/or pimelic anhydride) is capable of selectively supporting the growth of commensal S. epidermidis.
  • pimelic acid and/or pimelic anhydride
  • a biotin binder such as avidin
  • S. hominis has been shown to be s one of the main causes of axillary malodour.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition pour fournir des bénéfices pour le soin de la peau, tels que la réduction et/ou la prévention des mauvaises odeurs axillaires, en supportant sélectivement la croissance de souches commensales bénéfiques de S.epidermidis et/ou C. acnes dans le microbiome cutané humain, la composition comprenant au moins un composé de liaison à la biotine et au moins un précurseur pour la biosynthèse de la biotine choisi parmi l'acide pimélique, les sels de celui-ci ou un anhydride de celui-ci.
PCT/EP2021/063387 2020-05-20 2021-05-19 Compositions et méthodes pour fournir des bénéfices pour le soin de la peau WO2021234055A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21726914.1A EP4153124A1 (fr) 2020-05-20 2021-05-19 Compositions et méthodes pour fournir des bénéfices pour le soin de la peau

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20175848.9 2020-05-20
EP20175848 2020-05-20

Publications (1)

Publication Number Publication Date
WO2021234055A1 true WO2021234055A1 (fr) 2021-11-25

Family

ID=70802710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/063387 WO2021234055A1 (fr) 2020-05-20 2021-05-19 Compositions et méthodes pour fournir des bénéfices pour le soin de la peau

Country Status (2)

Country Link
EP (1) EP4153124A1 (fr)
WO (1) WO2021234055A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110163A1 (fr) * 2022-11-21 2024-05-30 Unilever Ip Holdings B.V. Procédés cosmétiques, kit de pièces et utilisation d'un ingrédient actif prébiotique pour la peau en combinaison avec un sel métallique antimicrobien pour fournir des bienfaits en matière de soins de la peau par reprofilage microbien de la peau

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780019A (en) * 1993-11-20 1998-07-14 Beiersdorf Ag Deodorising combination of agents based on α-ω alkanedicarboxylic acids and fatty acid partial glycerides
US20060233726A1 (en) * 2005-04-18 2006-10-19 Nia Sam D C SPF scalp sun screen protector
US20080152731A1 (en) * 2006-10-27 2008-06-26 Giuseppe Trigiante Compositions and method for hair loss prevention
US20100008897A1 (en) * 2008-07-09 2010-01-14 Susan Daly Composition for providing a benefit to a keratin-containing substrate
WO2010149437A1 (fr) * 2009-06-24 2010-12-29 Unilever Plc Composition d'après-shampooing à base de tensioactif anionique en c16-c22 et de composé gras en c16-c22
WO2019086327A1 (fr) * 2017-10-30 2019-05-09 Unilever N.V. Utilisation de niacinamide équilibrer le microbiome
WO2019115503A1 (fr) * 2017-12-13 2019-06-20 Dsm Ip Assets B.V. Mononitrate-monoacétate de propanediol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780019A (en) * 1993-11-20 1998-07-14 Beiersdorf Ag Deodorising combination of agents based on α-ω alkanedicarboxylic acids and fatty acid partial glycerides
US20060233726A1 (en) * 2005-04-18 2006-10-19 Nia Sam D C SPF scalp sun screen protector
US20080152731A1 (en) * 2006-10-27 2008-06-26 Giuseppe Trigiante Compositions and method for hair loss prevention
US20100008897A1 (en) * 2008-07-09 2010-01-14 Susan Daly Composition for providing a benefit to a keratin-containing substrate
WO2010149437A1 (fr) * 2009-06-24 2010-12-29 Unilever Plc Composition d'après-shampooing à base de tensioactif anionique en c16-c22 et de composé gras en c16-c22
WO2019086327A1 (fr) * 2017-10-30 2019-05-09 Unilever N.V. Utilisation de niacinamide équilibrer le microbiome
WO2019115503A1 (fr) * 2017-12-13 2019-06-20 Dsm Ip Assets B.V. Mononitrate-monoacétate de propanediol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHINORI MINE: "Egg Proteins and Peptides in Human Health-Chemistry, Bioactivity and Production", CURRENT PHARMACEUTICAL DESIGN, vol. 13, no. 9, 1 March 2007 (2007-03-01), pages 875 - 884, XP055036403, ISSN: 1381-6128, DOI: 10.2174/138161207780414278 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110163A1 (fr) * 2022-11-21 2024-05-30 Unilever Ip Holdings B.V. Procédés cosmétiques, kit de pièces et utilisation d'un ingrédient actif prébiotique pour la peau en combinaison avec un sel métallique antimicrobien pour fournir des bienfaits en matière de soins de la peau par reprofilage microbien de la peau

Also Published As

Publication number Publication date
EP4153124A1 (fr) 2023-03-29

Similar Documents

Publication Publication Date Title
US8318678B2 (en) Cosmetic compositions
CA2606140C (fr) Preparation cutanee externe
US10596093B2 (en) Cosmetic use as deodorant active agent of a siliceous material obtained by hydrolysis and condensation of a tetraalkoxysilane and of a C7-C20-alkyltrialkoxysilane
KR20120054102A (ko) 보존제로서의 바닐린 유도체의 용도, 보존 방법, 화합물 및 조성물
JP2001172176A (ja) 皮膚改善剤
JPH0445486B2 (fr)
ES2247030T3 (es) Utilizacion de cuerpos grasos especificos que permiten modificar las propiedades fisico-quimicas de la piel y/o de las mucosas como agentes que impiden o reducen la adhesion de los microorganismos sobre estas ultimas.
EP4153124A1 (fr) Compositions et méthodes pour fournir des bénéfices pour le soin de la peau
JPH10182346A (ja) 化粧料
JP2000355515A (ja) 化粧料組成物
EP3068366B1 (fr) Utilisation comme agent déodorant d'un dérivé salifié d'acide salicylique, seul ou en mélange
US20040220260A1 (en) Use of mono-or di-esters of cinnamic acid or of one of its derivatives and vitamin C, as donor of NO
JP2004506615A (ja) 天然又は再構築表皮を改善するためのセラミド前駆物質を含有する組成物と得られた皮膚等価物
WO2024110163A1 (fr) Procédés cosmétiques, kit de pièces et utilisation d'un ingrédient actif prébiotique pour la peau en combinaison avec un sel métallique antimicrobien pour fournir des bienfaits en matière de soins de la peau par reprofilage microbien de la peau
WO2021233614A1 (fr) Compositions et méthodes permettant d'apporter des bénéfices pour le soin du cuir chevelu
RU2383328C2 (ru) Трансдермальный гель для области вокруг глаз "silky touch"
KR20030005258A (ko) 케라틴 물질의 화장용 처리에 있어서의 알콜디하이드로게나아제 저해제의 용도
JP2002145719A (ja) 化粧料
CN104363887B (zh) 包含吡啶二甲酸酯和葡萄糖与脂肪酸的酯的组合物、方法与用途
JP2002087928A (ja) 化粧用保湿剤および化粧料
JPH111422A (ja) 化粧料
US20220177520A1 (en) Peptides inhibiting androgen receptor activity, and cosmetics composition using same
US20030039669A1 (en) Use of a composition containing an effective quantity of at least one chelating agent for partially or totally reducing the symptoms associated with histamine release in the organism
JP2003002810A (ja) 化粧品
WO2024104742A1 (fr) Procédé d'inhibition de croissance de microbes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21726914

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021726914

Country of ref document: EP

Effective date: 20221220